Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0M71T)

• Drug Name: Efatutazone Drug Info
• Synonyms: Inolitazone; Efatutazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
• Cross-matching ID:
  PubChem CID: 9832447
  ChEBI ID: CHEMBL3545280
  CAS Number: CAS 223132-37-4
  TTD Drug ID: D0Y8NZ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Ribosome biogenesis in eukaryotes	2.19	0.00e+0	52/108 (48.15%)	NXT1;IMP4;RAN;...
IL-17 signaling pathway	2.12	0.00e+0	84/94 (89.36%)	S100A8;CXCL2;S100A9;...
Malaria	2.06	0.00e+0	44/50 (88%)	SDC1;IL1B;CD36;...
Proteasome	2.01	2.36e-3	44/46 (95.65%)	PSMA3;PSMA6;PSMA1;...
DNA replication	1.89	5.67e-3	34/36 (94.44%)	POLE2;PCNA;POLE3;...
Viral protein interaction with cytokine and cytokine re...	1.88	6.29e-3	84/100 (84%)	CXCL2;CXCL14;CXCL3;...
NF-kappa B signaling pathway	1.86	8.09e-3	90/104 (86.54%)	CXCL2;CXCL3;IL1B;...
TNF signaling pathway	1.85	9.44e-3	103/112 (91.96%)	CXCL2;CXCL3;CCL20;...
Biosynthesis of unsaturated fatty acids	1.84	8.39e-3	21/27 (77.78%)	ELOVL6;ELOVL1;ELOVL2;...
Fatty acid elongation	1.82	7.55e-3	19/27 (70.37%)	ELOVL6;ACAA2;ELOVL1;...
Rheumatoid arthritis	1.80	1.03e-2	78/93 (83.87%)	CXCL2;CXCL3;CCL20;...
Steroid biosynthesis	1.72	2.68e-2	19/20 (95%)	SQLE;MSMO1;LBR;...
Legionellosis	1.72	2.47e-2	51/57 (89.47%)	CXCL2;CXCL3;CYCS;...
RNA transport	1.70	2.36e-2	128/186 (68.82%)	NXT1;EIF2S1;RAN;...
Cytokine-cytokine receptor interaction	1.65	3.97e-2	246/295 (83.39%)	CXCL2;CXCL14;CXCL3;...
Prion disease	1.65	4.01e-2	209/273 (76.56%)	PPIF;CYCS;IL1B;...
Pyrimidine metabolism	1.64	4.33e-2	40/56 (71.43%)	PNP;UPP1;ENPP1;...
Inositol phosphate metabolism	-1.88	2.11e-2	66/73 (90.41%)	MTMR4;INPP5B;SACM1L;...
Other glycan degradation	-1.98	1.05e-2	13/18 (72.22%)	GLB1;HEXB;ENGASE;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼